Relevant bibliographies by topics / Nimotuzumab

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Book chapters
  4. Conference papers
  5. Reports

Academic literature on the topic 'Nimotuzumab'

Author: Grafiati
Published: 5 June 2025
Last updated: 15 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Nimotuzumab.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Nimotuzumab"

1

Li, Jiwei, Tao Wu, Manbo Cai, et al. "Prognostic analysis of nimotuzumab combined with concurrent chemoradiotherapy in locally advanced cervical cancer: A multicenter real-world study." Journal of Clinical Oncology 42, no. 16_suppl (2024): 5532. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.5532.

Full text
Abstract:
5532 Background: Nimotuzumab is a monoclonal antibody against EGFR, which can improve the radiotherapy efficacy of nasopharyngeal carcinoma with EGFR positive. Most cervical cancers are induced by virus and express EGFR. Therefore, this study explores the efficacy and safety of Nimotuzumab combined with concurrent chemoradiotherapy (CCRT) in locally advanced cervical cancer (LACC). Methods: Information on patients with stage IIB-IVa cervical cancer who received CCRT combined with Nimotuzumab or CCRT alone at five cancer centers from January 2021 to December 2022 were collected. Nimotuzumab was administered 200mg once a week for a total of 6 weeks, starting on the same day as CCRT. The imaging examination was carried out 2 months after the end of radiotherapy. The reduction rate of lesions = (pre-treatment diameter - post-treatment diameter)/pre-treatment diameter. Patients were classified into the Nimotuzumab group and No-Nimotuzumab group. Categorical variables were compared using the χ2 test or Fisher’s exact test. Clinical outcomes were analyzed using the Kaplan–Meier method with log-rank test. Results: There are 224 patients enrolled, median age 57 years (32–90 years). The median follow-up time was 20 months (12–36months). The 2-year overall survival (OS) and progression-free survival (PFS) rates were 93% and 89.5%, respectively. The objective response rate (ORR) was 91.96%. There were 64 patients in Nimotuzumab group and 160 patients in No-Nimotuzumab group. The number of patients in Nimotuzumab group with stage IIIC and IVa, as well as those without chemotherapy, is higher than that in No-Nimotuzumab group. There was no significant difference between the Nimotuzumab and No-Nimotuzumab groups in terms of 2-year OS rate (93.2% vs.93%, p = 0.895), and PFS rate (96.2% vs.90.4%, p = 0.645). However, The Nimotuzumab group has a better CR rate (53.13% vs. 35%, P=0.012), ORR (98.44% vs. 89.38%, p=0.024), and reduction rate of cervical lesions (79.26% vs.70.94%, p=0.046) compared to the No-Nimotuzumab group (Table). Also, there was no significant difference between the Nimotuzumab and No-Nimotuzumab groups in terms of hematological toxicity (89.83% vs. 94.48%, p=0.730), nausea and vomiting (35.59% vs. 38.19, p=0.865), radiation proctitis (45% vs. 33.1%, p=0.371), radiation cystitis (8.47% vs. 7.64%, p=0.761), and grade 3-4 toxicities. Conclusions: The combination of Nimotuzumab and CCRT for LACC has a better reduction rate of lesions and ORR, without increasing side effects. [Table: see text]
APA, Harvard, Vancouver, ISO, and other styles
2

Kumar, Ashok, Nilotpal Chakravarty, Sharad Bhatnagar, and G. S. Chowdhary. "Efficacy and safety of concurrent chemoradiotherapy with or without Nimotuzumab in unresectable locally advanced squamous cell carcinoma of head and neck: Prospective comparative study - ESCORT-N study." South Asian Journal of Cancer 08, no. 02 (2019): 108–11. http://dx.doi.org/10.4103/sajc.sajc_38_18.

Full text
Abstract:
Abstract Background: Nimotuzumab is an anti-epidermal growth factor receptor monoclonal antibody which can be added to chemoradiotherapy (CRT) to improve efficacy for management of locally advanced squamous cell carcinoma of the head and neck (LASCCHN). We prospectively evaluated the efficacy and safety of nimotuzumab with CRT for LASCCHN and compared with CRT alone. Materials and Methods: In this prospective study, 29 LASCCHN (Stage III–IVb) patients received Nimotuzumab plus CRT or CRT alone. Treatment included six cycles of cisplatin (40–50 mg/week) or carboplatin (area under the curve-based), nimotuzumab (200 mg/week), and radiotherapy (60–70 Gy). Tumor response was evaluated as per response evaluation criteria in solid tumors criteria. MoS was estimated using the Kaplan–Meier method. Toxicity and adverse events (AE's) were assessed as per CTCAE v 4.0. Results: At 24 weeks after completion of treatment, the tumor response rate (complete response, partial response, stable disease) was 53.3% and 35.7% favoring nimotuzumab arm while progression of disease was 40% and 35.7% in Nimotuzumab plus CRT and CRT groups, respectively. However, the objective response rate was 57% and 30% in favor of nimotuzumab arm. At median follow-up of 45.5 months, MoS was 33 months in Nimotuzumab plus CRT and 27 months in CRT group. The 5-year survival rate was 33.3% in Nimotuzumab plus CRT versus 7.1% in CRT group. Nimotuzumab was observed to be safe with no additional AE's such as hypersensitivity, hypomagnesemia, and allergic reaction was reported. Conclusion: Addition of Nimotuzumab to standard CRT showed improved survival rate in unresectable, LASCCHN patients without producing additional toxicity.
APA, Harvard, Vancouver, ISO, and other styles
3

Kumar, Ashok, Nilotpal Chakravarty, Sharad Bhatnagar, and G. S. Chowdhary. "Efficacy and safety of concurrent chemoradiotherapy with or without Nimotuzumab in unresectable locally advanced squamous cell carcinoma of head and neck: Prospective comparative study - ESCORT-N study." South Asian Journal of Cancer 08, no. 02 (2019): 108–11. http://dx.doi.org/10.4103/sajc.sajc_38_18.

Full text
Abstract:
Abstract Background: Nimotuzumab is an anti-epidermal growth factor receptor monoclonal antibody which can be added to chemoradiotherapy (CRT) to improve efficacy for management of locally advanced squamous cell carcinoma of the head and neck (LASCCHN). We prospectively evaluated the efficacy and safety of nimotuzumab with CRT for LASCCHN and compared with CRT alone. Materials and Methods: In this prospective study, 29 LASCCHN (Stage III–IVb) patients received Nimotuzumab plus CRT or CRT alone. Treatment included six cycles of cisplatin (40–50 mg/week) or carboplatin (area under the curve-based), nimotuzumab (200 mg/week), and radiotherapy (60–70 Gy). Tumor response was evaluated as per response evaluation criteria in solid tumors criteria. MoS was estimated using the Kaplan–Meier method. Toxicity and adverse events (AE's) were assessed as per CTCAE v 4.0. Results: At 24 weeks after completion of treatment, the tumor response rate (complete response, partial response, stable disease) was 53.3% and 35.7% favoring nimotuzumab arm while progression of disease was 40% and 35.7% in Nimotuzumab plus CRT and CRT groups, respectively. However, the objective response rate was 57% and 30% in favor of nimotuzumab arm. At median follow-up of 45.5 months, MoS was 33 months in Nimotuzumab plus CRT and 27 months in CRT group. The 5-year survival rate was 33.3% in Nimotuzumab plus CRT versus 7.1% in CRT group. Nimotuzumab was observed to be safe with no additional AE's such as hypersensitivity, hypomagnesemia, and allergic reaction was reported. Conclusion: Addition of Nimotuzumab to standard CRT showed improved survival rate in unresectable, LASCCHN patients without producing additional toxicity.
APA, Harvard, Vancouver, ISO, and other styles
4

Tikum, Anjong Florence, Anand Krishnan Nambisan, Jessica Pougoue Ketchemen, et al. "Simultaneous Imaging and Therapy Using Epitope-Specific Anti-Epidermal Growth Factor Receptor (EGFR) Antibody Conjugates." Pharmaceutics 14, no. 9 (2022): 1917. http://dx.doi.org/10.3390/pharmaceutics14091917.

Full text
Abstract:
Matuzumab and nimotuzumab are anti-EGFR monoclonal antibodies that bind to different epitopes of domain III of EGFR. We developed 89Zr-matuzumab as a PET probe for diagnosis/monitoring of response to treatment of a noncompeting anti-EGFR nimotuzumab antibody drug conjugate (ADC) using mouse colorectal cancer (CRC) xenografts. We developed 89Zr-matuzumab and performed quality control in EGFR-positive DLD-1 cells. The KD of matuzumab, DFO-matuzumab and 89Zr-matuzumab in DLD-1 cells was 5.9, 6.2 and 3 nM, respectively. A competitive radioligand binding assay showed that 89Zr-matuzumab and nimotuzumab bound to noncompeting epitopes of EGFR. MicroPET/CT imaging and biodistribution of 89Zr-matuzumab in mice bearing EGFR-positive xenografts (HT29, DLD-1 and MDA-MB-231) showed high uptake that was blocked with pre-dosing with matuzumab but not with the noncompeting binder nimotuzumab. We evaluated nimotuzumab-PEG6-DM1 ADC in CRC cells. IC50 of nimotuzumab-PEG6-DM1 in SNU-C2B, DLD-1 and SW620 cells was dependent on EGFR density and was up to five-fold lower than that of naked nimotuzumab. Mice bearing the SNU-C2B xenograft were treated using three 15 mg/kg doses of nimotuzumab-PEG6-DM1, and 89Zr-matuzumab microPET/CT was used to monitor the response to treatment. Treatment resulted in complete remission of the SNU-C2B tumor in 2/3 mice. Matuzumab and nimotuzumab are noncompeting and can be used simultaneously.
APA, Harvard, Vancouver, ISO, and other styles
5

G, Adang H., Anung Pujiyanto, Abdul Mutalib, et al. "Profil Distribusi dan Klirens Pengkontras CT SCAN AuNP-PAMAM G4- NIMOTUZUMAB disimulasikan menggunakan Senyawa 198AuNP-PAMAM G4-NIMOTUZUMAB." Jurnal Kimia Terapan Indonesia 18, no. 01 (2016): 37–43. http://dx.doi.org/10.14203/jkti.v18i01.38.

Full text
Abstract:
Riset nanopartikel emas sebagai senyawa pengkontras CT-Scan telahdimulai sejak 3 tahun lalu di Indonesia. Riset interaksi antibodi monoklonal,khususnya nimotuzumab, dengan reseptor EGFR/HER1 dimulai sejak lima tahun lalu dan telah dimanfaatkan untuk penyiapan senyawa pengkontras MRI (Magnetic Resonance Imaging) spesifik target melalui pelabelan konjugat dendrimer-nimotuzumab dengan radionuklida. Sintesis senyawa AuNP-PAMAM G4-Nimotuzumab untuk diagnosis dan terapi pada kanker paru-paru telah berhasil dilakukan di PTRR dan hasil karakterisasinya dengan menggunakan beberapa metode seperti KCKT (Kromatografi Cair Kinerja Tinggi), SDS (Sodium Dodecyl Sulphate) page elektroforesa dan TEM (Transmission Electron Microscopy) menunjukkan bahwa senyawa yang terbentuk adalah sebagai AuNP-PAMAM G4-Nimotuzumab. Pada penelitian ini telah dilakukan uji pre klinis dari senyawa pengkontras AuNPPAMAM G4-nimotuzumab meliputi uji distribusi dan klirens dengan disimulasikan menggunakan senyawa radioaktiv 198AuNP-PAMAM G4- nimotuzumab. Hasil uji distribusi senyawa 198AuNP-PAMAM G4- nimotuzumab menunjukkan penimbunan pada beberapa organ seperti ginjal, hati dan limpa, sedangkan dari hasil uji klirens diperoleh waktu paruh biologis senyawa tersebut adalah 11.77 hari. Hasil pemeriksaan terhadap urin dengan menggunakan kolom PD-10 (Sephadex G25) menunjukkan bahwa ~ 85 % yang dikeluarkan lewat urin masih berbentuk AuNP-PAMAM G4- Nimotuzumab. Hasil pencitraan dengan alat autoradiography menunjukkan bahwa sampai dengan 48 jam setelah penyuntikan, akumulasi radioaktivitas yang terdeteksi masih terdapat pada hati.
APA, Harvard, Vancouver, ISO, and other styles
6

Solomon, Viswas Raja, Kris Barreto, Wendy Bernhard, et al. "Nimotuzumab Site-Specifically Labeled with 89Zr and 225Ac Using SpyTag/SpyCatcher for PET Imaging and Alpha Particle Radioimmunotherapy of Epidermal Growth Factor Receptor Positive Cancers." Cancers 12, no. 11 (2020): 3449. http://dx.doi.org/10.3390/cancers12113449.

Full text
Abstract:
To develop imaging and therapeutic agents, antibodies are often conjugated randomly to a chelator/radioisotope or drug using a primary amine (NH2) of lysine or sulfhydryl (SH) of cysteine. Random conjugation to NH2 or SH groups can require extreme conditions and may affect target recognition/binding and must therefore be tested. In the present study, nimotuzumab was site-specifically labeled using ∆N-SpyCatcher/SpyTag with different chelators and radiometals. Nimotuzumab is a well-tolerated anti-EGFR antibody with low skin toxicities. First, ΔN-SpyCatcher was reduced using tris(2-carboxyethyl)phosphine (TCEP), which was followed by desferoxamine-maleimide (DFO-mal) conjugation to yield a reactive ΔN-SpyCatcher-DFO. The ΔN-SpyCatcher-DFO was reacted with nimotuzumab-SpyTag to obtain stable nimotuzumab-SpyTag-∆N-SpyCatcher-DFO. Radiolabeling was performed with 89Zr, and the conjugate was used for the in vivo microPET imaging of EGFR-positive MDA-MB-468 xenografts. Similarly, ∆N-SpyCatcher was conjugated to an eighteen-membered macrocyclic chelator macropa-maleimide and used to radiolabel nimotuzumab-SpyTag with actinium-225 (225Ac) for in vivo radiotherapy studies. All constructs were characterized using biolayer interferometry, flow cytometry, radioligand binding assays, HPLC, and bioanalyzer. MicroPET/CT imaging showed a good tumor uptake of 89Zr-nimotuzumab-SpyTag-∆N-SpyCatcher with 6.0 ± 0.6%IA/cc (n = 3) at 48 h post injection. The EC50 of 225Ac-nimotuzumab-SpyTag-∆N-SpyCatcher and 225Ac-control-IgG-SpyTag-∆N-SpyCatcher against an EGFR-positive cell-line (MDA-MB-468) was 3.7 ± 3.3 Bq/mL (0.04 ± 0.03 nM) and 18.5 ± 4.4 Bq/mL (0.2 ± 0.04 nM), respectively. In mice bearing MDA-MB-468 EGFR-positive xenografts, 225Ac-nimotuzumab-SpyTag-∆N-SpyCatcher significantly (p = 0.0017) prolonged the survival of mice (64 days) compared to 225Ac-control IgG (28.5 days), nimotuzumab (28.5 days), or PBS-treated mice (30 days). The results showed that the conjugation and labeling using SpyTag/∆N-SpyCatcher to nimotuzumab did not significantly (p > 0.05) alter the receptor binding of nimotuzumab compared with a non-specific conjugation approach. 225Ac-nimotuzumab-SpyTag-∆N-SpyCatcher was effective in vitro and in an EGFR-positive triple negative breast cancer xenograft model.
APA, Harvard, Vancouver, ISO, and other styles
7

Pendharkar, D., S. Gupta, M. K. Pal, S. Hakim, and T. Rashid. "Feasibility of combining humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 (nimotuzumab) with chemotherapy-A study of toxicity profile and tolerance." Journal of Clinical Oncology 25, no. 18_suppl (2007): 14151. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.14151.

Full text
Abstract:
14151 Background. Anti-EGFR antibodies have been approved in combination with radiotherapy for the treatment of head and neck squamous cell carcinoma(SCCHN) and being tried in glioblastoma multiforme(GBM). The overall toxicity profile is tolerable. There is no data available on Humanized Anti EGFR antibody in combination with chemotherapeutic agents. Nimotuzumab, the humanized MAb derived from ior EGFR/R3, is a genetically engineered IgG1, with high affinity and specificity to EGFR. This study was undertaken to record the immediate and early toxicity of combining Nimotuzumab with various chemotherapeutic agents. Methods. Patients with SCCHN and GBM, scheduled to receive chemotherapy alone were additionally given 400mg of Nimotuzumab, every three weeks. Two patients with GBM received weekly Nimotuzumab 200 mg along with radiation and chemotherapy. Overall 19 events have been analyzed. The chemoschedules used in combination with Nimotuzumab included-Docetaxel, Carboplatin and Capecitabine in patients with SCCHN and Temozolamide/ Procarbazine in GBM. Antibody infusion was always preceded by antihistaminics and dexamethasone. Results.The combination of Nimotuzumab with chemotherapy was well tolerated. There were no acute infusion related events. No febrile, allergic or anaphylactic episodes were seen. Cutaneous rash classical of other EGFR blockers was not recorded. Two episodes of grade 3 diarrhea, and four events of asthenia were seen. Dryness of the mouth was a complaint in SCCHN patients. None of the patients showed neurological or cardiovascular adverse events. Hematological and biochemical derangements were not observed. Conclusion. Nimotuzumab can safely be combined with various chemotherapeutic agents .There is no unacceptable toxicity associated with combination of chemotherapy and humanized anti-EGFR monoclonal antibody. New schedules combining Nimotuzumab and chemotherapy can be safely explored. No significant financial relationships to disclose.
APA, Harvard, Vancouver, ISO, and other styles
8

Wu, Sangang, Runjie Wang, Yifeng Yu, et al. "Efficacy of nimotuzumab added to concurrent chemoradiotherapy after induction chemotherapy for patients with locally advanced nasopharyngeal carcinoma." Journal of Clinical Oncology 42, no. 16_suppl (2024): 6024. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.6024.

Full text
Abstract:
6024 Background: To investigate the efficacy and toxicities associated with adding nimotuzumab to concurrent chemoradiotherapy (CCRT) in locally advanced nasopharyngeal carcinoma (LANPC) patients who received induction chemotherapy (IC). Methods: Patients with stage III-IVA nasopharyngeal carcinoma who received IC (TPF/TP/GP) and platinum-based CCRT between January 2017 and October 2021 were retrospectively included. We performed propensity score matching (PSM) to balance and control confounding factors, and the matching variables included gender, age, T stage, N stage, and Epstein-Barr virus (EBV) status. Patients were divided into two treatment groups: CCRT+nimotuzumab (200mg iv, weekly for 7 courses) and CCRT alone. Primary endpoints were overall survival (OS) and disease-free survival (DFS), the secondary endpoints were locoregional recurrence-free survival (LRFS) and distant metastasis-free survival (DMFS). Results: We screened 242 patients in the analysis. After PSM, 121 (50.0%) and 121 (50.0%) had CCRT+nimotuzumab and CCRT alone, respectively. The 3-year OS was 95.4% and 88.0% in those with and without nimotuzumab treatment (P=0.041), and the 3-year DFS of the CCRT+nimotuzumab group was significantly better than that in the CCRT alone group (90.3% vs. 77.5%, P=0.003). Similar LRFS was found between those with and without nimotuzumab treatment (96.5% vs. 93.7%, P=0.297). The 3-year DMFS for CCRT+nimotuzumab versus CCRT alone was 92.9% versus 82.5% (P=0.008). No significant differences in major toxicities were found between the two treatment arms including hematologic toxicities, hepatoxicity, nephrotoxicity, gastrointestinal reactions, and mucositis (P>0.05). Conclusions: The addition of nimotuzumab to CCRT after IC in LANPC has shown promising results in treatment outcomes and acceptable toxicities.
APA, Harvard, Vancouver, ISO, and other styles
9

Huang, Yanping, Xiangdan Cuan, Weiwei Zhu, et al. "An EGCG Derivative in Combination with Nimotuzumab for the Treatment of Wild-Type EGFR NSCLC." International Journal of Molecular Sciences 24, no. 18 (2023): 14012. http://dx.doi.org/10.3390/ijms241814012.

Full text
Abstract:
Inhibiting the tyrosine kinase activity of epidermal growth factor receptor (EGFR) using small-molecule tyrosine kinase inhibitors (TKIs) or monoclonal antibodies is often ineffective in treating cancers harboring wild-type EGFR. Given the fact that EGFR possesses a kinase-independent pro-survival function, more effective inhibition of EGFR-mediated signals is therefore necessary. In this study, we investigated the effects of using a combination of low-dose nimotuzumab and theasinensin A to evaluate whether the inhibitory effect of nimotuzumab on NCI-H441 cancer cells was enhanced. Here, theasinensin A, a novel epigallocatechin-3-gallate (EGCG) derivative, was identified and its potent anticancer activity against wild-type EGFR NSCLC was demonstrated in vitro; the anticancer activity was induced through degradation of EGFR. Mechanistic studies further revealed that theasinensin A bound directly to the EGFR extracellular domain, which decreased interaction with its ligand EGF in combination with nimotuzumab. Theasinensin A significantly promoted EGFR degradation and repressed downstream survival pathways in combination with nimotuzumab. Meanwhile, treatment with theasinensin A and nimotuzumab prevented xenograft growth, whereas the single agents had limited effect. Thus, the combination therapy of theasinensin A with nimotuzumab is a powerful candidate for treatment of wild-type EGFR cancers.
APA, Harvard, Vancouver, ISO, and other styles
10

Prabhash, Kumar, Kanaka Govind Babu, Ashok K. Vaid, et al. "Nimotuzumab plus chemotherapy versus chemotherapy alone in advanced non-small cell lung cancer: A phase II, open-label, multicenter, randomized study." Journal of Clinical Oncology 31, no. 15_suppl (2013): 8053. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.8053.

Full text
Abstract:
8053 Background: To evaluate the safety and efficacy of nimotuzumab in combination with chemotherapy (docetaxel and carboplatin) versus chemotherapy alone in stage IIIB/IV non-small cell lung cancer (NSCLC) patients. Methods: This multicenter, open-label, phase II study, randomized 110 patients to receive nimotuzumab plus chemotherapy (nimotuzumab group) or chemotherapy alone (control group), and comprised concomitant, maintenance, and follow-up phases. Nimotuzumab (200 mg) was administered once weekly for 13 weeks during the first 2 phases with 4 cycles of chemotherapy; docetaxel (75 mg/m2) and carboplatin (area under the curve [AUC] = 5 mg/ml*min), every 3 weeks for a maximum of 4 cycles during the concomitant phase. The primary endpoint was objective response rate (ORR; sum of complete response [CR] and partial response [PR]). Secondary endpoints, overall survival (OS), and progression-free survival (PFS) were estimated using Kaplan-Meier method. Efficacy was evaluated on the intent-to-treat (ITT) and efficacy-evaluable (EE) sets. Safety was assessed from adverse events (AEs) and serious adverse events (SAEs) data. Results: ORR was significantly higher in the nimotuzumab group than in the control group in the ITT (54% vs. 34.5%; P=0.04) population. CR and PR were achieved in 3.6% and 50% patients, respectively, in the nimotuzumab group, and in 4% and 30.9% patients, respectively, in the control group. No significant differences in median PFS and OS were observed. Safety profiles were comparable between the 2 groups. Conclusions: Nimotuzumab plus chemotherapy significantly improved ORR as compared to chemotherapy alone; the combination was safe and well tolerated in stage IIIB/IV NSCLC patients.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Nimotuzumab"

1

Petřík, Michal. "Studium stability monoklonální protilátky nimotuzumab modifikované chelátorem DOTA radioaktivně značené luteciem-177 ([177Lu]Lu-hR3(p-SCN-Bn)DOTA)." Master's thesis, 2010. http://www.nusl.cz/ntk/nusl-279146.

Full text
Abstract:
The higher expressivity of the gene for the receptor of epidermal growth factor (EGF) and consequently higher number of receptors (EGFR) on the surface of cells is closely linked with the tumour proliferation of these cells and with poor prognosis for patients. For such reason the EGFR became one of the main objectives in the therapy of tumours. Nimotuzumab (also known as h-R3) is humanized monoclonal antibody which blocks receptor for epidermal growth factor. The object of this thesis was to determinate radiochemical purity of this antibody conjugated with bifunctional chelator DOTA and marked by luthecium, possibly purification of this antibody and consequently determination of its stability in different environments. In acetate buffer pH = 7, in an environment of the surplus of competitive ligand EDTA and in plasma of rats. Adequate analytic methods were used for these tasks: high-efficiency liquid chromatography, gel permeation chromatography and chromatography on thin layer. The results of the thesis demonstrated that this way of modification for further radiolabelling is not appropriate for large protein structures such as Nimotuzumab
APA, Harvard, Vancouver, ISO, and other styles
2

Korec, David. "Studium stability monoklonální protilátky nimotuzumab modifikované chelátorem DTPA radioaktivně značené luteciem-177 ([177Lu]Lu-hR3(p-SCN-Bn)DTPA)." Master's thesis, 2010. http://www.nusl.cz/ntk/nusl-279509.

Full text
Abstract:
Stability studies of monoclonal antibody nimotuzumab modified with chelator DTPA radiolabelled with lutetium-177 ([177Lu]Lu-hR3(p-SCN-Bn)DTPA) Diploma thesis David Korec Charles University in Prague, Faculty of Pharmacy in Hradec Králové Department of Biophysics and Physical Chemistry In this work was target to study the stability of monoclonal antibody Nimotuzumab, which was modified with chelator DTPA radiolabelled with radioactive Lutetium-177 ([177Lu] Lu-hR3 (p- SCN-Bn) DTPA). The radiochemical purity of the supplied antibody was 61%. For other uses had to purified. The chelator EDTA adds in addition for the labeled antibody. It has lower stability constant than the original chelating agent. He can catch the free ligand, which is excreted through the kidneys. For biodistribution studies is needed to ensure the highest purity that was well described by the distribution of radiopharmaceuticals in small bodies. Purification was used for gel permeation chromatography Sephadex. Purity was about 99%. HPLC analysis after one hour showed a small percentage of low molecular weight forms. It may be modified ligand with radionuclide or free radionuclide. At times long after purification the HPLC profile of low molecular weight fraction appeared in two peaks. They are therefore both options possible. The...
APA, Harvard, Vancouver, ISO, and other styles
3

Fasih, Aisha. "111In-labeled Nimotuzumab Modified with Nuclear Localization Sequences (NLS): An Auger Electron-emitting Radiotherapeutic Agent for EGFR-overexpressing and Trastuzumab-resistant Breast Cancer." Thesis, 2011. http://hdl.handle.net/1807/29548.

Full text
Abstract:
Objective: The cytotoxic property of anti-EGFR-1 monoclonal-antibody nimotuzumab modified with nuclear localization sequence and radiolabeled with 111In was evaluated in trastuzumab-resistant breast cancer cells. Methods: 111In-nimotuzumab-NLS was constructed and its immunoreactivity was determined. Cellular and nuclear uptake was evaluated by cell fractionation. Finally, the cytotoxicity of conjugates (111In-nimotuzumab/111In-nimotuzumab-NLS) was studied by clonogenic assays. Results: The immunoreactivity of 111In-nimotuzumab-NLS was conserved. 111In-nimotuzumab-NLS exhibited 2-fold higher nuclear translocation as compared to 111In-nimotuzumab in MDA-MB-468 cells. Nuclear importation of 111In-nimotuzumab-NLS in MDA-MB-468 cells was 4-fold and 6-fold higher than moderate and low EGFR expressing cell lines, respectively. Clonogenic survival (CS) for MDA-MB-468 cells showed 111In-nimotuzumab-NLS to be 10-folds and 60-folds more potent than 111In-nimotuzumab and nimotuzumab, respectively. Moderate killing for TrR1 and MDA-MB-231 was observed. 111In-hEGF showed significantly higher cytotoxicity and 2-fold higher γ-H2AX foci integrated density/nuclear-area as compared to 111In-nimotuzumab-NLS. Preserved selectivity of 111In-nimotuzumab-NLS makes it an excellent drug for treating cancers.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Nimotuzumab"

1

Tridente, Giuseppe. "Nimotuzumab." In Adverse Events with Biomedicines. Springer Milan, 2013. http://dx.doi.org/10.1007/978-88-470-5313-7_28.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Ramos, Tania Crombet. "Nimotuzumab: A Humanized Anti-EGFR Antibody." In Handbook of Therapeutic Antibodies. Wiley-VCH Verlag GmbH & Co. KGaA, 2014. http://dx.doi.org/10.1002/9783527682423.ch61.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Aroeman, Nur Akbar, and Andrio Raymos. "The Role of Nimotuzumab and an Anti-Egfr Mab, in the Treatment of Locally Advanced Scchn." In Advances in Health Sciences Research. Atlantis Press International BV, 2023. http://dx.doi.org/10.2991/978-94-6463-280-4_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Bone, U., R. Cabanas, G. Saurez-Martinez, et al. "Anti-EGFR nimotuzumab for DIPG in recurrent or children with high grade glioma: 10 years." In Stem Cell Oncology. CRC Press, 2018. http://dx.doi.org/10.1201/9781351190152-55.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Nimotuzumab"

1

Muñiz-Hernández, Saé, Vanessa Izquierdo-Sánchez, Jorge A. Mendoza-Desión, Carolina González-Torres, and Oscar Arrieta. "Abstract 25: Efect of nimotuzumab on malignant pleural mesothelioma cell lines." In Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-25.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Jaramillo, Maria L., Suzanne Grothe, Jason Baardsnes, et al. "Abstract 1778: Nimotuzumab, a humanized antiepidermal growth factor receptor antibody, interacts with EGFRvIII." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-1778.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Putra, A. R., Y. Yulizar, R. Ritawidya, S. Juliyanto, A. Fikri, and I. Darojatin. "Piper nigrum extract-mediated synthesis of Fe3O4 nanoparticles and their conjugation with nimotuzumab." In PROCEEDINGS OF THE 7TH INTERNATIONAL SYMPOSIUM ON CURRENT PROGRESS IN MATHEMATICS AND SCIENCES 2021. AIP Publishing, 2024. http://dx.doi.org/10.1063/5.0212651.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Fasih, Aisha, Ray Reilly, and Ilia Tikhomirov. "Abstract 4551: 111In-NLS-Nimotuzumab: A potent auger electron-emitting radiotherapeutic agent for EGFR-overexpressing breast cancer." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-4551.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Nagane, Motoo, Yusuke Nitta, Saki Shimizu, Yukiko Shishido-Hara, and Yoshiaki Shiokawa. "Abstract 5473: Anti-EGFR monoclonal antibody nimotuzumab enhances temozolomide-induced growth suppression of mutant EGFR expressing glioma xenografts." In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-5473.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Huang, Xuelei, Yipeng Ren, Qing Xi, Lei Zhang, Chongjian Fu, and Rongfa Bu. "Abstract 2437: Fluorescent imaging in animal model of human tongue squamous cell carcinomain vivoby Nimotuzumab conjugated near-infrared quantum dots and small molecule fluorescent dye." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-2437.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Mutsaers, Anthony J., Shan Man, Ping Xu, Ilia Tikhomirov, and Robert S. Kerbel. "Abstract C49: Combination treatment with metronomic cyclophosphamide and the EGFR monoclonal antibody nimotuzumab is efficacious and non‐toxic in a preclinical model of advanced triple negative breast cancer." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Nov 15-19, 2009; Boston, MA. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/1535-7163.targ-09-c49.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Hou, Tao, Min Lu, Xiayan Zhao, Yan He, Chunhong Hu, and Ping Liu. "Abstract CT266: Safety and efficacy of nimotuzumab in combination with chemotherapy in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): A phase II study." In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-ct266.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Nimotuzumab"

1

Yuan, Yan, Yaru Guo, Jiuzhou Chen, Miao Fang, and Yong Xin. Nimotuzumab combined with chemoradiotherapy for the treatment of cervical cancer: A meta-analysis of randomized controlled trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.4.0098.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Nimotuzumab' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography